Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Next Previous
Trial Profile

A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cetuximab (Primary) ; Divarasib (Primary) ; Erlotinib (Primary) ; Inavolisib (Primary) ; Migoprotafib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Appendiceal cancer; Cholangiocarcinoma; Colorectal cancer; Duodenal neoplasms; Endometrial cancer; Gastric cancer; Lung cancer; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech

Most Recent Events

  • 12 Feb 2026 Planned End Date changed from 24 Sep 2025 to 31 Dec 2027.
  • 12 Feb 2026 Planned primary completion date changed from 24 Sep 2025 to 31 Dec 2027.
  • 16 Oct 2025 Planned End Date changed from 28 Feb 2026 to 24 Sep 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top